Adenocarcinoma of the Endometrium

Lifshitz, Samuel; Bernstein, Steven G.

doi:10.1007/978-1-4612-5525-3_8

Cited by 2 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some adverse effects of oestrogen therapy may also be related to the total circulating oestrogen concentration. This may be the case for endometrial cancer (Lifshitz & Bernstein, 1983) and for breast cancer although the evidence that the latter is linked to oestrogen treatment is less certain (Edman, 1983). Since unconjugated oestrogen levels are substantially higher with oral treatment than equipotent transdermal treatment, we would suggest that the risk of cancer developing with the former is likely to be higher.…”

Section: Discussionmentioning

confidence: 92%

Comparison of the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonadotrophin release, bone turnover and climacteric symptoms in postmenopausal women

Selby

McGarrigle

1989

Maturitas

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 92%

Comparison of the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonadotrophin release, bone turnover and climacteric symptoms in postmenopausal women

Selby

McGarrigle

1989

Maturitas

View full text Add to dashboard Cite

Comparison of the Effects of Oral and Transdermal Oestradiol Administration on Oestrogen Metabolism, Protein Synthesis, Gonadotrophin Release, Bone Turnover and Climacteric Symptoms in Postmenopausal Women

Selby

Mcgarrigle

Peacock

1989

Clinical Endocrinology

View full text Add to dashboard Cite

We compared the effect of administering oestradiol via the transdermal or oral routes in six and eight postmenopausal women respectively. Although both treatments achieved similar plasma levels of oestradiol, oral administration led to much greater increases in plasma levels of oestrone and the sulphates and glucuronides of oestradiol, oestrone and oestriol than transdermal treatment (P less than 0.001). Both treatments reduced plasma FSH; from 42 +/- 10 (SE) IU/l to 30 +/- 2 IU/l with oral and from 46 +/- 7 IU/l to 28 +/- 6 IU/l with transdermal treatment. Urine calcium excretion fell from 0.41 +/- 0.06 (molar ratio to creatinine) to 0.17 +/- 0.02 with oral and from 0.25 +/- 0.06 to 0.13 +/- 0.02 with transdermal treatment. Patients' symptoms were improved by both treatments. These changes were related to the plasma oestradiol concentration but not to that of oestrone. Oral, but not transdermal, treatment stimulated hepatic protein synthesis as shown by increased plasma levels of both vitamin-D-binding globulin and sex-hormone-binding globulin. We conclude that although both oral and transdermal oestradiol reduce postmenopausal bone loss, gonadotrophin secretion and symptoms, oral treatment also leads to hepatic stimulation and extensive metabolism of oestradiol, both of which may increase side-effects without conferring additional benefit.

show abstract

Adenocarcinoma of the Endometrium

Cited by 2 publications

References 53 publications

Comparison of the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonadotrophin release, bone turnover and climacteric symptoms in postmenopausal women

Comparison of the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonadotrophin release, bone turnover and climacteric symptoms in postmenopausal women

Comparison of the Effects of Oral and Transdermal Oestradiol Administration on Oestrogen Metabolism, Protein Synthesis, Gonadotrophin Release, Bone Turnover and Climacteric Symptoms in Postmenopausal Women

Contact Info

Product

Resources

About